To our surprise, FZD10 was significantly hypermethylated and downregulated in a majority of the tumor tissues, and the methylation ratios of CpG units 1 and 38–39 in the FZD10 promoter were significantly higher in stage I lung cancer than in stage II and III disease. Here, FZD10 is linked to lung cancer.